Literature DB >> 10604724

Schedule-dependent cytotoxicity of SN-38 in p53 wild-type and mutant colon adenocarcinoma cell lines.

R H te Poele1, S P Joel.   

Abstract

In this study the effects of SN-38 on colon adenocarcinoma cell lines expressing wild-type p53 (LS174T) or mutant non-functional p53 (HT29) have been investigated. On exposure to SN-38, HT29 cells rapidly progressed through G1 and S and arrested in G2/M. Release and concomitant increase in apoptosis after 48 h was concentration- and time-dependent (P < 0.001), being more rapid at higher concentrations, but reaching plateau at 10 ng ml(-1) with prolonged exposure. LS174T cells showed only a small increase in apoptosis, and only at high concentrations (50-100 ng ml(-1)). The main effect of SN-38 in LS174T cells was prolonged cell cycle arrest, which was independent of concentration. Arrest occurred in all phases of the cell cycle, with the distribution depending on concentration (P < 0.001) and not duration (P > 0.05). With increasing concentration, LS174T cells arrested in G2/M, S and G1. Cell cycle arrest was coincident with increased p53 expression in each phase of the cell cycle. Expression in G1 increased with time and concentration (P < 0.001, P = 0.01 respectively)whereas in S and G2/M p53 expression increased only with time (P< 0.001). Dose-dependent p53-associated G1 arrest, in the absence of DNA synthesis indicates an additional cytotoxic mechanism for SN-38, which requires higher concentrations than the S phase mechanism, and detection of which seems to involve p53. For incubations with the same ED (exposure x duration), apoptosis in HT29 cells was significantly higher for prolonged exposure to lower concentrations, whereas in LS174T cells there was a trend towards increased apoptosis with shorter exposures to higher concentrations, indicating a schedule effect of SN-38. Although expression of wild-type p53 leads to a more rapid induction of apoptosis, SN-38 cytotoxicity was generally greater in cells with mutant p53, as wild-type cells escaped apoptosis by p53 associated prolonged cell cycle arrest. Thus, pulsed schedules with higher doses may be more effective in cells expressing wild-type p53, whereas continued exposure with protracted schedules may be more active in cells expressing mutant p53.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10604724      PMCID: PMC2362968          DOI: 10.1038/sj.bjc.6694370

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  29 in total

Review 1.  Assays of cell viability: discrimination of cells dying by apoptosis.

Authors:  Z Darzynkiewicz; X Li; J Gong
Journal:  Methods Cell Biol       Date:  1994       Impact factor: 1.441

2.  DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts.

Authors:  A Di Leonardo; S P Linke; K Clarkin; G M Wahl
Journal:  Genes Dev       Date:  1994-11-01       Impact factor: 11.361

3.  The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors.

Authors:  L Dubrez; F Goldwasser; P Genne; Y Pommier; E Solary
Journal:  Leukemia       Date:  1995-06       Impact factor: 11.528

4.  New naphthacenecarboxamide antibiotics, TAN-1518 A and B, have inhibitory activity against mammalian DNA topoisomerase I.

Authors:  T Horiguchi; K Hayashi; S Tsubotani; S Iinuma; S Harada; S Tanida
Journal:  J Antibiot (Tokyo)       Date:  1994-05       Impact factor: 2.649

5.  Specific DNA binding by different classes of human p53 mutants.

Authors:  N Rolley; S Butcher; J Milner
Journal:  Oncogene       Date:  1995-08-17       Impact factor: 9.867

6.  Distinct patterns of cell cycle disturbance elicited by compounds interfering with DNA topoisomerase I and II activity.

Authors:  M Poot; K H Hiller; S Heimpel; H Hoehn
Journal:  Exp Cell Res       Date:  1995-05       Impact factor: 3.905

Review 7.  CPT-11: clinical experience in phase I studies.

Authors:  J P Armand
Journal:  Semin Oncol       Date:  1996-02       Impact factor: 4.929

8.  Clinical studies of irinotecan alone and in combination with cisplatin.

Authors:  M Fukuoka; N Masuda
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

9.  Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.

Authors:  P J Houghton; P J Cheshire; J D Hallman; L Lutz; H S Friedman; M K Danks; J A Houghton
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

10.  Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors.

Authors:  G Catimel; G G Chabot; J P Guastalla; A Dumortier; C Cote; C Engel; A Gouyette; A Mathieu-Boué; M Mahjoubi; M Clavel
Journal:  Ann Oncol       Date:  1995-02       Impact factor: 32.976

View more
  6 in total

1.  Effects of a histone deacetylase inhibitor, sodium butyrate, on 53-kDa protein expression and sensitivity to anticancer drugs of pancreatic cancer cells.

Authors:  Masaki Kitazono; Hiroyuki Shinchi; Sumiya Ishigami; Shinichi Ueno; Shoji Natsugoe
Journal:  Curr Ther Res Clin Exp       Date:  2010-06

2.  The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines.

Authors:  David Davidson; Yunzhe Wang; Raquel Aloyz; Lawrence Panasci
Journal:  Invest New Drugs       Date:  2012-10-09       Impact factor: 3.850

Review 3.  Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years.

Authors:  Mariusz Panczyk
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

4.  Topoisomerase I inhibitor SN-38 effectively attenuates growth of human non-small cell lung cancer cell lines in vitro and in vivo.

Authors:  Dharmendra Kumar Maurya; Rie Ayuzawa; Chiyo Doi; Deryl Troyer; Masaaki Tamura
Journal:  J Environ Pathol Toxicol Oncol       Date:  2011       Impact factor: 3.567

5.  Differential sensitization of two human colon cancer cell lines to the antitumor effects of irinotecan combined with 5-aza-2'-deoxycytidine.

Authors:  Shuko Hakata; Jun Terashima; Yu Shimoyama; Kouji Okada; Shiho Fujioka; Erika Ito; Wataru Habano; Shogo Ozawa
Journal:  Oncol Lett       Date:  2018-01-26       Impact factor: 2.967

6.  Evidence that exposure of the telomere 3' overhang sequence induces senescence.

Authors:  Guang-Zhi Li; Mark S Eller; Reza Firoozabadi; Barbara A Gilchrest
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-06       Impact factor: 11.205

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.